Featured Research

from universities, journals, and other organizations

Third trimester group B streptococcus test doesn't accurately predict presence during labor

Date:
February 11, 2011
Source:
Society for Maternal-Fetal Medicine
Summary:
Many women are having different test results for Group B streptococcus between their routine third trimester screening and a rapid test performed at the time of labor.

In a study presented February 11 at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers presented findings that show that many women are having different test results for Group B streptococcus (GBS) between their routine third trimester screening and a rapid test performed at the time of labor.

GBS early-onset sepsis is a leading cause of neonatal infection. GBS is a bacterium that normally exists in the genital tracts of one-third of women; this bacterium comes and goes in the genital tracts of many women -- often without women knowing that they have it. It can lead to an infection and can put an infant at risk if it is present in the mother during delivery. Women are routinely tested for GBS in their third trimester. If the bacterium is present, these women are given antibiotics during labor. Two days are needed to obtain results from the standard culture, which prevents women from being screened in labor. However, a new rapid test that returns results in approximately one hour can be administered at the time of labor.

"Most women are currently screened for GBS in their last trimester, but even if the test is negative, GBS can still develop before women give birth," said Brett Young, M.D, an obstetrician undergoing training in high risk obstetrics at Massachusetts General Hospital. "We know that two-thirds of infants with GBS sepsis are born to mothers with negative third-trimester cultures, so we wanted to see how many women with a negative GBS test in the third trimester have a positive GBS result right before delivery. These babies in particular are at risk for acquiring GBS infection because the mothers are not given appropriate antibiotics in labor."

Young and her colleagues enrolled women in their study who presented to labor and delivery with an antepartum GBS culture. GBS cultures and rapid tests were performed during labor and compared to the third trimester GBS culture results

Among 559 women, GBS prevalence was 19.5% with the third-trimester culture and 23.8% with culture performed on samples collected during labor. Compared with the culture obtained during labor, the third-trimester culture correctly predicted GBS positivity at the time of labor only 69% of the time versus the rapid test which correctly predicted GBS positivity 91% of the time. The incidence of GBS discordance from the late third trimester to labor was 10%. Compared with women who identified as Caucasian, African-American and Hispanic women were significantly more likely to have discordant culture results.

The study found that the rapid GBS test used when women present in labor has excellent test characteristics and may be a useful adjunct to the third trimester culture for accurately detecting the presence of GBS at the time of labor.

"We found that African-American and Hispanic women were significantly more likely to have results that converted from the third trimester to the time of labor, so the use of the rapid test might be even more beneficial in those groups," said Young.


Story Source:

The above story is based on materials provided by Society for Maternal-Fetal Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Maternal-Fetal Medicine. "Third trimester group B streptococcus test doesn't accurately predict presence during labor." ScienceDaily. ScienceDaily, 11 February 2011. <www.sciencedaily.com/releases/2011/02/110211074552.htm>.
Society for Maternal-Fetal Medicine. (2011, February 11). Third trimester group B streptococcus test doesn't accurately predict presence during labor. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/02/110211074552.htm
Society for Maternal-Fetal Medicine. "Third trimester group B streptococcus test doesn't accurately predict presence during labor." ScienceDaily. www.sciencedaily.com/releases/2011/02/110211074552.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins